Effects of treatment with vitamin D3 in Hashimoto's Thyroiditis with vitamin D deficiency on Thyroid function, antithyroid antibodies and metabolic markers

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014120520216N1

Enrollment

Registered

2015-12-02

Start date

2014-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis. Autoimmune thyroiditis: Hashimoto's thyroiditis, Temporary hashitoxicosis, Lymphadenoid thyroiditis, Lymphocytic thyroiditis, Lymphomatosis Stroma

Interventions

Intervention 1: intervention group 1: 50.000 units of Vitamin D prescription weekly and per oral for 12 weeks. Intervention 2: control group: placebo prescription weekly per oral for 12 weeks.

Treatment - Drugs

Placebo

intervention group 1: 50.000 units of Vitamin D prescription weekly and per oral for 12 weeks

control group: placebo prescription weekly per oral for 12 weeks

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 20 to 60 years; anti thyroid peroxidase antibody positive; serum 25 hydroxyl vitamin D 3 is less than 20 nanogram per milliliter; euthyroid or hypothyroid; if Levothyroxin or other metabolic drugs like Statins, Metformin consumed, starting time was more than 6 months ago. Exclusion criteria: immunosuppressor drugs intake before the study; dietary supplementation intake per oral or injections before study; comorbid disease ; severe weight loss; insulin taking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
25, hydroxyl vitamin D3. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.;TPOAb. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.;Thyroid Stimulating Hormone (TSH). Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.	—

Measure

Time frame

25, hydroxyl vitamin D3. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.;TPOAb. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.;Thyroid Stimulating Hormone (TSH). Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.

—

Secondary

Measure	Time frame
Calcium. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.;PTH. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: serum level measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Parichehr Vahabi Anaraki

Isfahan University of Medical Science

pari.vahabi@med.mui.ac.ir+98 31 3669 7913

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026